SAN CARLOS, Calif., June 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing novel pain management therapies, today announced it will report results for its first quarter of 2007 on Wednesday, June 13, 2007, after the market closes.
A conference call to review the results will begin at 5:00 p.m. EDT (2:00 p.m. PDT) and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.
The conference call dial-in numbers are (877) 407-4018 (USA) or (201) 689-8471 (International). In addition, a dial-up replay of the conference call will be available beginning June 13, 2007 at 8:00 p.m. EDT (5:00 p.m. PDT) and ending on June 23, 2007. The replay telephone number is USA (877) 660-6853, International (201) 612-7415, Account Number: 3055, Conference ID Number: 244959.
A live Web cast of the call will also be available from the Investor Relations section on the corporate Web site at http://www.neurogesx.com. A Web cast replay can be accessed on the corporate web site beginning Wednesday, June 13, 2007, at approximately 6:30 p.m. EDT. The replay will remain available until July 13, 2007.
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and diabetic neuropathy. NeurogesX’s late stage product portfolio is led by product candidate NGX-4010, a topical patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Two Phase III clinical trials with NGX-4010 have been completed and have met their primary endpoints, one in PHN and one in HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the announcement of quarterly results and the potential benefits of NeurogesX’ lead product candidate, NGX- 4010. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited past results of clinical trials may not be indicative of future clinical trials results; NeurogesX’ product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010. For further information regarding these and other risks related to NeurogesX’ business, investors should consult NeurogesX’ filings with the Securities and Exchange Commission.
NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Investors / Media (650) 508-2116 Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 scarrington@theruthgroup.comjrando@theruthgroup.com
NeurogesX, Inc.
CONTACT: Stephen Ghiglieri of NeurogesX, Inc., +1-650-508-2116; orInvestors and Media, Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, both of The Ruth Group for NeurogesX, Inc.
Web site: http://www.neurogesx.com/
